Juvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis
of unknown origin with onset before age of 16 years. Pivotal studies in the past 5 years have …

Systemic juvenile idiopathic arthritis (sJIA) has long been recognized as unique among
childhood arthritides, because of its distinctive clinical and epidemiological features …

Background Juvenile idiopathic arthritis can be refractory to some or all treatment regimens,
therefore new medications are needed to treat this population. This trial assessed the …

Background Growing knowledge about cellular interactions in the immune system, including
the central role of cytokine networks, has lead to new treatments using monoclonal …

Systemic juvenile idiopathic arthritis and adult-onset Still's disease are rare
autoinflammatory disorders with common features, supporting the recognition of these being …

The treatment of juvenile idiopathic arthritis (JIA) is evolving. The growing number of
effective drugs has led to successful treatment and prevention of long-term sequelae in most …

Aims/hypothesis In adults, circulating inflammatory mediators and activated CD14++
monocytes link obesity to its metabolic and cardiovascular complications. However, it is …

Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly administered to children and
adolescents with juvenile idiopathic arthritis (JIA) and pediatric inflammatory bowel disease …

Background: Systemic juvenile idiopathic arthritis (SJIA) is a chronic childhood arthropathy
with features of autoinflammation. Early inflammatory SJIA is associated with expansion and …

Systemic juvenile idiopathic arthritis (SJIA) is a disease marked with arthritis and several
features of systemic inflammation including fevers, rashes, hepatosplenomegaly …